Table 1.
Demographic and clinical characteristics of study non-depressed MS patients (n = 112)
| Characteristics | N (%) |
|---|---|
| Gender | |
| Male | 40 (35.7) |
| Female | 72 (64.3) |
| Marital status | |
| Single | 46 (41.1) |
| Married | 62 (55.4) |
| Divorced | 4 (3.6) |
| Education level | |
| Primary | 6 (5.4) |
| Intermediate | 10 (8.9) |
| Secondary | 20 (17.9) |
| Bachelor | 64 (57.1) |
| Postgraduate | 12 (10.7) |
| Region | |
| Southern | 34 (30.4) |
| Middle | 42 (37.5) |
| East | 24 (21.4) |
| West | 12 (10.7) |
| Age (years), mean ± SD 32.6 ± 8.9 | |
| Age at disease onset (years), mean ± SD 26 ± 8.2 | |
| Disease duration (years), mean ± SD 3.5 ± 1.9 | |
| Number of admissions, mean ± SD 0.8 ± 1.3 | |
| Number of attacks during last 2 years, mean ± SD 1.6 ± 1.9 | |
| Medications used | |
| Interferon beta-1b (betaferon) | 36 (32.1) |
| Teriflunomide (aubagio) | 20 (17.9) |
| Dimethylfumarate (tecfidera) | 24 (21.4) |
| Rituximab (rituxan) | 18 (16.1) |
| Alemtuzumab (lemetrada) | 14 (12.5) |
| Routes of drug administration | |
| Oral | 20 (17.9) |
| Subcutaneous | 52 (46.4) |
| Intramuscular | 32 (28.6) |
| Intravenous | 8 (7.1) |